Efficacy and safety of YOXINTINE for depression: a double-blinded, randomized, placebo-controlled, phase 2 clinical trial DOI
Zaiquan Dong, Qi Shen, Hanwen Zhu

et al.

Phytomedicine, Journal Year: 2024, Volume and Issue: 136, P. 156204 - 156204

Published: Nov. 14, 2024

Language: Английский

Traditional Chinese medicine decoctions and Chinese patent medicines for the treatment of depression: Efficacies and mechanisms DOI

Wei Zhuang,

Shao-Li Liu,

Shengyan Xi

et al.

Journal of Ethnopharmacology, Journal Year: 2023, Volume and Issue: 307, P. 116272 - 116272

Published: Feb. 13, 2023

Language: Английский

Citations

57

Perturbation-theory machine learning for mood disorders: virtual design of dual inhibitors of NET and SERT proteins DOI Creative Commons
Alejandro Speck‐Planche, Valeria V. Kleandrova, M. Natália D. S. Cordeiro

et al.

BMC Chemistry, Journal Year: 2025, Volume and Issue: 19(1)

Published: Jan. 2, 2025

Abstract Mood disorders affect the daily lives of millions people worldwide. The search for more efficient therapies mood remains an active field research. In silico approaches can accelerate inhibitors against protein targets related to disorders. Here, we developed first model perturbation-theory machine learning based on a multiplayer perceptron network (PTML-MLP) simultaneous prediction and design virtual dual-target two proteins associated with disorders, namely norepinephrine serotonin transporters (NET SERT, respectively). PTML-MLP had accuracy around 80%. From chemical point view, could accurately identify both single- present in dataset used build it. Through application fragment-based topological (FBTD) approach, molecular descriptors (multi-label graph-based indices) were physicochemically structurally interpreted. Such interpretations enabled (a) extraction different fragments positive influence enhancement activity (b) four new drug-like molecules by assembling (fusing and/or connecting) several suitable fragments. designed predicted exhibit NET SERT proteins. These predictions, together estimated druglikeness suggest that be promising chemotypes considered future synthesis biological experimentation context treatments

Language: Английский

Citations

2

Clinical specificity profile for novel rapid acting antidepressant drugs DOI Creative Commons

Mauro Scala,

Giuseppe Fanelli, Diana De Ronchi

et al.

International Clinical Psychopharmacology, Journal Year: 2023, Volume and Issue: 38(5), P. 297 - 328

Published: June 29, 2023

Mood disorders are recurrent/chronic diseases with variable clinical remission rates. Available antidepressants not effective in all patients and often show a relevant response latency, range of adverse events, including weight gain sexual dysfunction. Novel rapid agents were developed the aim overcoming at least part these issues. drugs target glutamate, gamma-aminobutyric acid, orexin, other receptors, providing broader pharmacodynamic mechanisms, that is, expected to increase possibility personalizing treatments on individual profile. These new combining action, tolerable profile, higher effectiveness specific symptoms, which relatively poorly targeted by standard antidepressants, such as anhedonia reward, suicidal ideation/behaviours, insomnia, cognitive deficits, irritability. This review discusses specificity profile namely 4-chlorokynurenine (AV-101), dextromethorphan-bupropion, pregn-4-en-20-yn-3-one (PH-10), pimavanserin, PRAX-114, psilocybin, esmethadone (REL-1017/dextromethadone), seltorexant (JNJ-42847922/MIN-202), zuranolone (SAGE-217). The main is provide an overview efficacy/tolerability compounds mood having different symptom/comorbidity patterns, help clinicians optimization risk/benefit ratio when prescribing drugs.

Language: Английский

Citations

26

Advancements Exploring Major Depressive Disorder: Insights on Oxidative Stress, Serotonin Metabolism, BDNF, HPA Axis Dysfunction, and Pharmacotherapy Advances DOI Creative Commons
Ana Salomé Correia, Nuno Vale

International Journal of Translational Medicine, Journal Year: 2024, Volume and Issue: 4(1), P. 176 - 196

Published: March 5, 2024

Major depressive disorder (MDD), a prevalent mental illness, is marked by complex mixture of biological factors. This review focuses on the roles oxidative stress, tryptophan-serotonin metabolism, brain-derived neurotrophic factor (BDNF), and hypothalamic–pituitary–adrenal (HPA) axis in MDD’s pathophysiology. Oxidative defined as an imbalance between pro-oxidants antioxidants, closely linked to neurobiological changes. The tryptophan (TRP)-/serotonin (5-HT) metabolic pathway also known be crucial mood regulation, with its dysregulation being central aspect MDD. Additionally, BDNF, key for neuronal growth plasticity, often shows alterations MDD patients, supporting role disorder’s progression. Furthermore, HPA axis, which manages stress response, frequently disrupted MDD, further contributing pathology. In addition exploring these mechanisms, this explores pharmacotherapy including new advances. These advancements treatment strategies are managing effectively. Understanding mechanisms latest pharmacological interventions essential developing more effective treatments

Language: Английский

Citations

8

The role of polyunsaturated fatty acids in neuronal signaling in depression and cognitive processes DOI
Katarzyna Stachowicz

Archives of Biochemistry and Biophysics, Journal Year: 2023, Volume and Issue: 737, P. 109555 - 109555

Published: Feb. 24, 2023

Language: Английский

Citations

17

A rare olive compound oleacein functions as a TrkB agonist and mitigates neuroinflammation both in vitro and in vivo DOI Creative Commons

Daiki Wakasugi,

Shinji Kondo, Farhana Ferdousi

et al.

Cell Communication and Signaling, Journal Year: 2024, Volume and Issue: 22(1)

Published: June 4, 2024

Abstract Background Neuroinflammation is widely acknowledged as a characteristic feature of almost all neurological disorders and specifically in depression- anxiety-like disorders. In recent years, there has been significant attention on natural compounds with potent anti-inflammatory effects due to their potential mitigating neuroinflammation neuroplasticity. Methods the present study, we aimed evaluate neuroprotective oleacein (OC), rare secoiridoid derivative found extra virgin olive oil. Our goal was explore BDNF/TrkB neurotrophic activity OC subsequently assess its for modulating neuroinflammatory response using human neuroblastoma cells (SH-SY5Y cells) an vivo model depression induced by lipopolysaccharide (LPS)-mediated inflammation. Results SH-SY5Y cells, exhibited dose-dependent increase BDNF expression. This enhancement absent when were co-treated inhibitors BDNF's receptor TrkB, well downstream molecules PI3K MEK. Whole-transcriptomics analysis revealed that upregulated cell cycle-related genes under normal conditions, while downregulating inflammation-associated LPS-induced conditions. Furthermore, surface plasmon resonance (SPR) assays demonstrated stronger more stable binding affinity TrkB compared positive control, 7,8-dihydroxyflavone. Importantly, bioluminescence imaging single oral dose significantly increased expression brains Bdnf-IRES-AkaLuc mice. administration at dosage 10 mg/kg body weight days reduced immobility time tail suspension test LPS-treated group. RT-qPCR decreased pro-inflammatory cytokines Tnfα , Il6 Il1β simultaneously enhancing Bdnf expression, both pro mature protein levels mice hippocampus. These changes comparable those control antidepressant drug fluoxetine. Additionally, microarray mouse confirmed could counteract inflammatory biological events. Conclusion Altogether, our study represents first report antineuroinflammatory properties via modulation activity. finding underscores therapeutic agent anxiety-related

Language: Английский

Citations

5

Special Issue: Molecular Research on Depression DOI Open Access
Magdalena Sowa-Kućma, Katarzyna Stachowicz

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(2), P. 643 - 643

Published: Jan. 14, 2025

Depressive disorders (DDs) are responsible for a significant burden of disease in the human population [...]

Language: Английский

Citations

0

Connecting the dots: Understanding and addressing the metabolic impact of antipsychotic and antidepressant medications DOI Open Access
Susanne U. Miedlich, J. Steven Lamberti

Annals of the New York Academy of Sciences, Journal Year: 2025, Volume and Issue: unknown

Published: March 12, 2025

Abstract Serious mental disorders such as schizophrenia and major depression are associated with considerable morbidity mortality, resulting in much shorter life expectancies those affected. The discovery of antipsychotic medications ushered improved health outcomes for people serious but also brought about increased due to their metabolic side effects, including obesity diabetes mellitus. Antidepressant have a more favorable effect profile, some can still cause weight gain hyperglycemia. In this narrative review, we discuss antidepressant medications’ mechanisms action, respective effectiveness treating psychosis depression, effects. addition, present therapeutic strategies minimizing cardiometabolic risks patients treated these by applying comprehensive, biopsychosocial approach.

Language: Английский

Citations

0

Efficacy of Paroxetine in Treating Depression Across Different Demographics: A Literature Review DOI
Mohammad Aamir Khan

Published: March 6, 2025

This literature review examines the efficacy of paroxetine, a Selective Serotonin Reuptake Inhibitor (SSRI), in treating depression among adolescents, elderly patients, postpartum women, and postmenopausal women.

Language: Английский

Citations

0

The Importance of α-Klotho in Depression and Cognitive Impairment and Its Connection to Glutamate Neurotransmission—An Up-to-Date Review DOI Open Access
Patrycja Pańczyszyn-Trzewik, Ewelina Czechowska, Katarzyna Stachowicz

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(20), P. 15268 - 15268

Published: Oct. 17, 2023

Depression is a serious neuropsychiatric disease affecting an increasing number of people worldwide. Cognitive deficits (including inattention, poor memory, and decision-making difficulties) are common in the clinical picture depression. impairment has been hypothesized to be one most important components major depressive disorder (MDD; referred as depression), although typical cognitive symptoms less frequent with depression than schizophrenia or bipolar (BD; sometimes manic-depressive disorder). The importance α-Klotho aging process well-documented. Growing evidence points role regulating other biological functions, including responses oxidative stress modulation synaptic plasticity. It proven that Klotho deficit may contribute development various nervous system pathologies, such behavioral disorders neurodegeneration. Given growing impairment, it assumed this protein molecular link between them. Here, we provide research review impairment. Furthermore, propose potential mechanisms (related glutamatergic transmission) α-Klotho-mediated regulation mental function.

Language: Английский

Citations

10